CVRx replaces chief revenue officer amid sales shift. (Moderate) Rhea-AI filing summary. CVRx, Inc. reported that the employment of Chief Revenue Officer Robert John terminated effective immediately on August 10, 2026, under circumstances that entitle him to severance pay and benefits in line with his employment agreement. The company also announced a sales leadership transition in which Paul Verrastro, a long-time CVRx executive with more than 30 years of medical device sales and marketing experience, has been appointed Interim Head of Sales effective immediately while a search for a permanent successor is conducted. Management stated that a revised commercial outlook and the need to improve commercial execution led to the change in sales leadership. Positive. Negative. * CVRx's Chief Revenue Officer departed effective August 10, 2026, with the change explicitly linked to a revised commercial outlook and the need to improve commercial execution, signaling potential challenges in the company's current sales performance. 8-K event classification. 2 items: 5.02, 9.01 Key figures. Key terms. Emerging growth company, neuromodulation, Breakthrough Device designation, cardiac resynchronization therapy (CRT), +1 more Faq. What leadership change did CVRX (CVRX) announce in this Form 8-K? CVRx announced that Chief Revenue Officer Robert John's employment terminated effective August 10, 2026. The company has begun a transition in sales leadership following his departure under severance-eligible circumstances defined in his employment agreement. Who will lead sales at CVRX (CVRX) after the Chief Revenue Officer's departure? CVRx appointed Paul Verrastro as Interim Head of Sales effective immediately. He will oversee the sales organization while the company conducts a search for a permanent successor to the Chief Revenue Officer role. Why did CVRX (CVRX) change its sales leadership team? President and CEO Kevin Hykes stated that a revised commercial outlook and need to improve commercial execution led CVRx to change sales leadership, indicating the move is driven by current commercial performance considerations. What experience does the new Interim Head of Sales at CVRX (CVRX) have? Interim Head of Sales Paul Verrastro brings more than 30 years of medical device sales and marketing experience. He has been with CVRx for over five years and previously served as Chief Marketing and Strategy Officer and a senior advisor on commercial execution. Does Robert John receive severance in connection with his departure from CVRX (CVRX)? Yes. CVRx disclosed that Robert John's employment terminated under circumstances entitling him to severance pay and benefits under his employment agreement, subject to the applicable conditions set forth in that agreement. What product focus does CVRX (CVRX) highlight in connection with this leadership transition? CVRx highlights Barostim, described as the first FDA-approved neuromodulation technology for improving heart failure symptoms. The device delivers electrical pulses to carotid baroreceptors to help restore autonomic balance in heart failure patients. AI-generated analysis. How Rhea-AI works. Not financial advice. Find StockTitan more easily in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google Available on EDGAR 08/11/2026 - 07:09 AM Accepted by SEC EDGAR 08/11/2026 - 07:09 AM Date of report (Date of earliest event reported): (Exact name of registrant as specified in its charter) (Address of principal executive offices) (Zip Code) (Registrant's telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). On August 10, 2026, the employment of Robert John, the Chief Revenue Officer of CVRx, Inc., terminated effective immediately, under circumstances entitling him to severance pay and benefits under his employment agreement, subject to the conditions therein. (d) Exhibits SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Filing Exhibits & attachments. 4 documents Press releases.

CVRx Inc reported Q2 2026 revenue of $15.7 million, up 16% year-over-year, with US revenue climbing 21% to $14.8 million. However, European revenue fell 31% to $900,000. The medical device company achieved an 87% gross margin, improving from 84% previously. Despite positive metrics, CVRx lowered its full-year 2026 revenue guidance to between $58 million and $60 million due to sales execution challenges. The company cited high sales force turnover, with roughly 60% of territory managers having joined within the last 18 months, straining training processes. Reimbursement showed improvement, with Medicare Advantage prior authorisation approval rates rising to 60% from 44% in 2025. Traditional Medicare claims are now paid at approximately 96% across all administrative contractors. CVRx ended the quarter with $64.6 million in cash. The company reported a net loss of $14 million, or $0.53 per share.

CVRx shares rose 11.6% to close at $5.86, driven by investor optimism following strong first-quarter 2026 results. The medical device company posted a loss of 50 cents per share on revenues of $14.8 million, with both figures exceeding Zacks Consensus Estimates. For the upcoming quarter, CVRx is expected to report a loss of $0.52 per share on revenues of $15.64 million, representing year-over-year improvements of 8.8% and 15.1%, respectively. However, the consensus earnings estimate has remained unchanged over the past 30 days. The stock currently carries a Zacks Rank of Hold. CVRx is part of the medical instruments industry, alongside companies like Steris, which gained 2.4% in the last session.